Biosimilar Sponsors May Be Going Overboard On Clinical Data, FDA Says

Studying multiple indications 'not the right way to approach biosimilars,' agency says; Amgen conducted more studies than needed for its proposed Humira biosimilar to enhance patient and physician confidence.